The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Kung, Hank F.

doi:10.1021/ml300058m

Cited by 102 publications

(85 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, it is eliminated swiftly from normal mouse brain (clearance t1/2 almost 8 minutes) [16]. However, there are two disadvantages for its commercial use: short half-life of 20 minutes and problematic manufacturing practice [17]. [5].…”

Section: 2mentioning

confidence: 99%

Gallium-68 radiotracers for Alzheimer’s plaque imaging

Barrios-Lopez¹,

Airaksinen²,

Bergström³

2015

J Diagn Imaging Ther

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a brain disorder with aggravating symptoms of memory loss and dementia mainly in the elderly population. Imaging tools of β-amyloid (Aβ) plaques are necessary for clinical and neuropsychological characteristics in AD. This is in order to gain global understanding of the disease by the design and selection of effective drugs. Positron emission tomography (PET) is a notable tool for drug advancement because of its high sensitivity and capacity to produce quantitative and kinetic data.

show abstract

Section: 2mentioning

confidence: 99%

Gallium-68 radiotracers for Alzheimer’s plaque imaging

Barrios-Lopez¹,

Airaksinen²,

Bergström³

2015

J Diagn Imaging Ther

View full text Add to dashboard Cite

show abstract

“…For several years, the Aβ plaques and NFTs have been identified and largely studied as the two neuropathological hallmarks of the disorder [1]. NFTs are intracellular aggregates, while Aβ plaques aggregated in the extracellular space.…”

Section: Pathophysiology and Clinical Manifestationmentioning

confidence: 99%

“…Studies performed postmortem on AD patients' brains showed, as neuropathological features, the presence of senile plaques (SPs) and neurofibrillary tangles (NFTs), characterized by β-amyloid (Aβ) peptides and highly phosphorylated tau proteins [1]. Indeed, the "Aβ hypothesis" suggests that the development of AD is due to the accumulation and deposition of Aβ peptide aggregates in the brain.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers for the early diagnosis of Alzheimer’s disease: The challenge of XXI century

Contino¹,

Cantore²,

Leopoldo³

et al. 2013

AAD

View full text Add to dashboard Cite

AD is the most common form of dementia among the aging population. The neuropathological alterations of AD are represented by the neurofibrillary tangles and extracellular amyloid plaques formation. These two hallmarks are routinely used as biomarkers for AD diagnosis and can allow the identification of the pathology in a late phase. The urgent need to develop probes for PET analysis that can be used in an early diagnosis of this disorder opened a new scenario in which new biomarkers involved in the first step of AD can be easily detected. Recently, an increasing number of studies indicated as new biomarkers P-gp, TLR4, MIR and free serum copper that are involved in the onset of AD. It has been extensively reported that a P-gp dysfunction in brain can be considered one of the causes of the AD accumulation in brain parenchyma and that the up-regulation of inflammatory gene expression and inflammatory signaling due to MIR and TLR4 modulated the development and the progression of AD.

show abstract

“…Among the available molecular imaging modalities, positron emission tomography (PET) is the best suited to achieve such goal, particularly based on amyloid-avid molecules radiolabelled with the cyclotron produced radionuclides carbon-11 ( 11 C) and fluorine-18 ( 18 F) (Kung 2012;Lee, Choe et al 2012;Ribeiro Morais, Paulo et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Radiosynthesis and in vivo evaluation of a 18F-labelled styryl-benzoxazole derivative for β-amyloid targeting

Morais¹,

Gano²,

Knieß

et al. 2013

Applied Radiation and Isotopes

View full text Add to dashboard Cite

The formation of β-amyloid deposits is considered a histopathological feature of Alzheimer´s disease (AD). In vivo molecular imaging by means of amyloid-avid radiotracers will allow for an early and conclusive diagnostic of AD. Herein, we describe the radiosynthesis of the radiofluorinated styryl benzoxazole derivative Highlights• Design of a fluorinated styryl benzoxazole derivative for detection of β-amyloid plaques.• Nucleophilic radiofluorination with readily available [ 18 F]KF.• Metabolism and biodistribution studies of the radiofluorinated styryl benzoxazole derivative.

show abstract

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Cited by 102 publications

References 6 publications

Gallium-68 radiotracers for Alzheimer’s plaque imaging

Gallium-68 radiotracers for Alzheimer’s plaque imaging

Biomarkers for the early diagnosis of Alzheimer’s disease: The challenge of XXI century

Radiosynthesis and in vivo evaluation of a 18F-labelled styryl-benzoxazole derivative for β-amyloid targeting

Contact Info

Product

Resources

About